NR4A1 and breast carcinoma: While the majority of early-phase clinical studies have focused on indolent tumors such as small, hormone receptor-positive lesions, emerging preclinical and translational research has begun to explore its use in more aggressive subtypes, including triple-negative and HER2-positive breast cancers.